Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Change in Accured Expenses (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Change in Accured Expenses for 14 consecutive years, with $20148.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 356.76% year-over-year to $20148.0, compared with a TTM value of $129212.0 through Nov 2025, up 221.43%, and an annual FY2025 reading of $101217.0, up 132.61% over the prior year.
  • Change in Accured Expenses was $20148.0 for Q4 2025 at CNBX Pharmaceuticals, down from $101589.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $304689.0 in Q2 2023 and bottomed at -$66141.0 in Q3 2023.
  • Average Change in Accured Expenses over 5 years is $44746.8, with a median of $17048.5 recorded in 2025.
  • The sharpest move saw Change in Accured Expenses plummeted 163.43% in 2021, then surged 41304.52% in 2022.
  • Year by year, Change in Accured Expenses stood at $22944.0 in 2021, then soared by 491.81% to $135784.0 in 2022, then tumbled by 103.34% to -$4533.0 in 2023, then plummeted by 73.11% to -$7847.0 in 2024, then skyrocketed by 356.76% to $20148.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for CNBX at $20148.0 in Q4 2025, $101589.0 in Q3 2025, and -$6474.0 in Q2 2025.